Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss

Barreto, Monique Antunes de Souza Chelminski; Bahmad, Fayez

doi:10.5935/1808-8694.20130133

Cited by 22 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior evidence related to this topic has been limited to infrequent cases in clinical trials, case reports, small clinical studies, and pharmacovigilance data from regulatory agencies . Common to all previous reports is the small sample size, limiting their abilities to quantify the risk.…”

Section: Discussionmentioning

confidence: 99%

“…safety signal, the FDA approved more stringent labeling alerting to the potential risk of sudden hearing loss in men by using PDE5 inhibitors. 7 Since then, additional data from mouse model, [10][11][12] case reports, [13][14][15] small clinical studies, 16,17 and pharmacovigilance 18 have been published, raising further concern. While the association is perhaps initially surprising, a plausible mechanism for PDE5 inhibitor ototoxicity involves the nitric oxide-cyclic guanosine monophosphate signaling pathway 13 that has also been implicated with ototoxicity of gentamicin and cisplatin 19,20 To date, no large postmarketing safety studies of PDE5 inhibitor ototoxicity have been reported.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population‐based cohort study

Liu

Antonelli

Dahm

et al. 2018

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population‐based cohort study

Liu

Antonelli

Dahm

et al. 2018

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…In 2012, unilateral sudden sensorineural hearing loss affecting two male PDE5 inhibitor users (age 37 and 43) was described by Barreto and Bahmad [27]. Unfortunately, neither the time after the hearing loss has occurred nor the dosage of PDE5 inhibitors was stated.…”

Section: Phosphodiesterase-5 (Pde5) Inhibitorsmentioning

confidence: 99%

Ototoxicity: Old and New Foes

Szczepek¹

2017

Advances in Clinical Audiology

View full text Add to dashboard Cite

Drug-induced ototoxicity has been known for centuries. Already in the seventeenth century, hearing loss was described to be a side effect of quinine. The post-World War II pharmaceutical industry boomed with the production of aminoglycoside antibiotics followed by diuretics and cytostatic drugs. Wide-spread and long-term usage of these medications brought the knowledge about their unwanted ototoxic effects. In the last decades, several new drugs appeared on the shelves of pharmacies and the hearing loss or tinnitus have been among the side effects of many of them. However, the awareness of community about new ototoxic medications is still not sufficient. New ototoxic drugs may belong to the class of phosphodiesterase-5 (PDE5) inhibitors, used to improve microcirculation and to treat erectile dysfunction. Moreover, interferons used for the therapy of hepatitis B and C, common painkiller paracetamol and hydrocodone, synthetic opioid methadone and the inhibitors of reverse transcriptase were demonstrated to induce adverse effects on hearing. Lastly, hearing loss linked to immunosuppressive drugs was documented in patients undergoing organ transplantation. Making the patients aware of adverse drug reactions and offering them audiological monitoring and intervention should be considered by respective therapists.

show abstract

“…O mesmo ocorreu em um estudo clínico de 2009 [80] . Um estudo de coorte de 2010, avaliando 11.525 homens, com 40 anos ou mais, por 2 anos, mostrou que a perda auditiva foi duas vezes mais comum entre utilizadores dos inibidores de PDE-5 82 . Mais estudos a respeito são necessários, mas alguma relação já é observada e precisa ter a atenção médica 78,80,81 .…”

Section: -Inibidores Da Pde-5 E Perda Auditivaunclassified

Pathophysiology, evaluation and treatment of erectile dysfunction: review article

Sarris

Nakamura

Fernandes

et al. 2016

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Sarris AB, Nakamura MK, Fernandes LGR, Staichak RL, Pupulim AF, Sobreiro BP. Fisiopatologia, avaliação e tratamento da disfunção erétil: artigo de revisão/ Pathophysiology, evaluation and treatment of erectile dysfunction: review article. Rev Med (São Paulo). 2016 jan.-mar.;95(1):18-29. RESUMO:A disfunção erétil (DE) é a incapacidade recorrente de obter e manter uma ereção que permita atividade sexual satisfatória, sendo a disfunção sexual que mais afeta os homens no envelhecimento. Estima-se que 50% dos homens acima de 40 anos apresentem essa disfunção. Como a prevalência é expressiva, torna-se necessária a realização de uma revisão da literatura sobre epidemiologia, fisiopatologia e tratamento acerca da DE, com o intuito de melhor compreensão da doença. A ereção é dependente de vários fatores como o relaxamento do músculo liso do corpo cavernoso, o aumento do fluxo arterial e a restrição do fluxo venoso de saída. Esses mecanismos podem estar prejudicados em várias doenças, sendo que, em alguns casos, a DE pode ser considerada como marcador precoce de problemas mais graves. Essa disfunção sexual apresenta várias etiologias: vascular, endócrina, neurológica, psicológica/psiquiátrica e relacionada às drogas ou às intervenções cirúrgicas. O próprio tratamento de algumas doenças de base pode ser a causa ou o agravamento da DE, como alguns anti-hipertensivos e antidepressivos. A principal explicação para a DE é a redução da disponibilidade de óxido nítrico, um importante vasodilatador. Contudo, fazem também parte de sua fisiopatologia a obstrução mecânica dos vasos sanguíneos e problemas de transmissão de estímulos neurológicos. A DE é primeiramente avaliada pelo método clínico, mas existem instrumentos avaliativos multidimensionais, sendo o Índice Internacional de Função Erétil considerado o padrão-ouro. O tratamento pontual para esta doença deve ser fundado na sua etiologia. Existem várias linhas de tratamento, sendo os inibidores da fosfodiesterase-5 e a psicoterapia (para DE psicogênica ou mista) os de primeira escolha, associados ou não à reposição de testosterona. Como segunda-linha, tem-se a injeção intracavernosa de substâncias vasoativas. Caso essas terapias não produzam resultado, a prótese peniana pode ser indicada. DESCRITORES:Disfunção erétil/fisiopatologia; Diabetes mellitus; Hipertensão; Fatores de risco; Literatura de revisão como assunto.ABSTRACT: Erectile dysfunction (ED) is the repeated inability to get and maintain an erection to enable satisfactory sexual activity and it's the most common sexual dysfunction in aging men. It is estimated that 50% of men older than 40 years old exhibit this dysfunction. As the prevalence is significant, it is necessary to carry out a literature review of epidemiology, pathophysiology and treatment on the ED in order to better understand the disease. The erection is dependent on various factors such as smooth muscle relaxation of corpus cavernosum, increasing blood flow and restriction of venous outflow. These mechanisms may be impaired in several diseases, and, in...

show abstract

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss

Abstract: Increased occurrence in clinical practice and scientific reports in the literature suggest that the phosphodiesterase type 5 inhibitors are considered a risk factor for sudden deafness. Further studies with larger samples and control groups are needed for better assessing this association.

Cited by 22 publications

References 13 publications

Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population‐based cohort study

Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population‐based cohort study

Ototoxicity: Old and New Foes

Pathophysiology, evaluation and treatment of erectile dysfunction: review article

Contact Info

Product

Resources

About